DAF
0.016
60%
ARV
0.003
-25%
DXN
0.385
40%
LIB
0.003
-25%
C7A
0.004
33.3%
RWL
0.15
-21.1%
FAU
0.008
33.3%
EPN
0.023
-20.7%
M2M
0.008
33.3%
CHM
0.016
-20%
RKB
0.004
33.3%
ERE
0.012
-20%
AXN
0.035
29.6%
FIN
0.004
-20%
NXL
1.832
28.6%
SP3
0.009
-18.2%
ACU
0.13
23.8%
KGN
3.72
-17.5%
AEU
0.56
21.7%
CDE
0.005
-16.7%
AUQ
0.045
21.6%
ENL
0.005
-16.7%
RRE
0.11
20.9%
RLG
0.005
-16.7%
COY
0.006
20%
CRR
0.006
-14.3%
GTN
0.24
20%
HYT
0.006
-14.3%
WRX
0.024
20%
RFT
0.006
-14.3%
14D
0.07
16.7%
UNT
0.006
-14.3%
CTO
0.014
16.7%
LML
0.007
-12.5%
LOT
0.28
16.7%
SPN
0.18
-12.2%
M4M
0.007
16.7%
EPI
0.405
-12%
WSR
0.007
16.7%
DTZ
0.023
-11.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CRSP U.S. FDA approved first therapy utilising CRISPR

The beginning of a new era in medicine: The U.S. FDA has today approved cell-based gene therapy Casgevy, marking the first FDA-approved therapy utilising the genome editing technology CRISPR (NASDAQ:CRSP) | https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
#FDA #CRISPR #shorts